Moteur de recherche d’entreprises européennes
Financement de l’UE (3 836 996 €) : Accélération précoce de la consommation de médicaments Hor27/08/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Accélération précoce de la consommation de médicaments
The development of effective novel drugs - especially for rare and neglected diseases - is one of the biggest challenges of the upcoming decades, as illustrated by the recent Ebola outbreak. Moreover, European innovation in new drug registrations is dramatically falling behind compared to the US and Asia. The principal aim of the AEGIS ITN is to implement the first comprehensive, intersectoral cross-disciplinary and structured curriculum for doctoral students in the European Research Area by establishing a unique training platform for the next generation of European researchers in early drug discovery. A significant added value is provided through networking with key European pharmaceutical companies. A key research aim of AEGIS is improving the efficiency and success of early stage drug development by combining innovative methods and techniques to tackle difficult but promising targets (i.e. protein-protein interactions), as potentially valuable drug targets are often neglected due to the high risk associated with their validation. The consortium joins leading academic and industry researchers in an open innovation environment for innovative drug development in Europe. It is supported by several additional partners and stakeholders in the field. Integrated training of the fellows takes place at the host institute and by secondments, research schools and individual training within the AEGIS network. The scientific training includes complementary skills, management, intellectual property rights, fund raising, communication and career planning. AEGIS will improve the availability of a highly skilled workforce for European industries and research, greatly enhance the employability and the career perspectives of young researchers for academia as well as for industry, and will be the seed of a sustainable development in innovative drug discovery, in particular for rare and neglected diseases.
| ? | |
| Astrazeneca AB | 263 659 € |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | 265 227 € |
| 258 061 € | |
| HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM für GESUNDHEIT UND UMWELT GmbH | 498 433 € |
| Institut Pasteur | 525 751 € |
| NOVARTIS PHARMA AG | 265 227 € |
| PHILIPPS UNIVERSITAET MARBURG | 498 433 € |
| Ridgeview Instruments AB | 263 659 € |
| Rijksuniversiteit Groningen | 510 749 € |
| Uniwersytet Jagiellonski | 224 137 € |
| Uppsala Universitet | 263 659 € |
https://cordis.europa.eu/project/id/675555
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Astex, Madrid, Espagne.
Les visualisations de "Astex - Financement de l’UE (3 836 996 €) : Accélération précoce de la consommation de médicaments"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
